Research programme: recombinant antibodies - AnaptysBio/Momenta Pharmaceuticals

Drug Profile

Research programme: recombinant antibodies - AnaptysBio/Momenta Pharmaceuticals

Alternative Names: Anti-FcRn antibody - Momenta Pharmaceuticals

Latest Information Update: 01 Dec 2014

Price : $50

At a glance

  • Originator AnaptysBio
  • Developer Momenta Pharmaceuticals
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Fc receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 01 Dec 2014 Preclinical trials in Autoimmune disorders in USA (Parenteral)
  • 08 Sep 2014 Momenta Pharmaceuticals exercises its option to acquire recombinant antibodies generated by AnaptysBio
  • 17 Dec 2013 Early research in Autoimmune disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top